PASADENA, Calif.--Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to provide engineering, procurement and construction management (EPCM) services for Biogen’s (NYSE: BIIB) new manufacturing facility in Luterbach, Switzerland.
Under the terms of the agreement, Jacobs is providing EPCM services for Biogen’s fourth manufacturing plant. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. The company currently manufactures therapies in Cambridge, Massachusetts; Research Triangle Park, North Carolina; and Hillerød, Denmark.
Plans for the new facility include state-of-the-art biotech manufacturing technology, which is expected to triple the company’s global capacity to produce large protein-based drugs known as biologics.
In making the announcement, Jacobs Global Life Sciences Senior Vice President Robert Norfleet stated, “We are pleased Biogen chose to work with us to meet its demands for increased manufacturing capacity. As the largest professional services provider to the biopharmaceutical industry, we look forward to providing innovative solutions that can help strengthen its medication supply system around the globe.”
Work on the facility was expected to begin in late 2015 with the plant fully operational by 2021.
Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies providing therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.
Jacobs is one of the world's largest and most diverse providers of technical professional and construction services.
Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2014 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.